We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA's Risk Evaluation Guidance Brings Clarity, Not Solutions

Law360 (April 26, 2019, 4:40 PM EDT) -- This April, the U.S. Food and Drug Administration issued final guidance clarifying how the FDA applies the factors in section 505-1 of the Federal Food, Drug and Cosmetic Act[1] to determine whether a risk evaluation and mitigation strategy is necessary to ensure that the benefits of a drug outweigh its risks.

Section 505-1 of the FD&C Act was created as part of the Food and Drug Administration Amendments Act of 2007. A REMS is a required risk management plan to ensure that the benefits of a drug outweigh its risks.

To approve a drug, the FDA must determine that the drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS